Franco Muggia investigador
Muggia, Franco M.
![Sudoc [ABES], France](/viaf/images/flags/SUDOC.png "Sudoc [ABES], France")
Muggia, Franco M., 1936-
Muggia, F.M. (Franco M.)
Muggia, Franco
VIAF ID: 67648825 (Personal)
Permalink: http://viaf.org/viaf/67648825
Preferred Forms
-
100 0 _
‡a
Franco Muggia
‡c
investigador
-
200 _ |
‡a
Muggia
‡b
Franco
-
100 1 _ ‡a Muggia, F.M. ‡q (Franco M.)
-
100 1 _ ‡a Muggia, Franco M
-
100 1 _ ‡a Muggia, Franco M.
-
100 1 _ ‡a Muggia, Franco M.
-
100 1 _
‡a
Muggia, Franco M.
-
100 1 _
‡a
Muggia, Franco M.
-
100 1 _ ‡a Muggia, Franco M.
-
100 1 _
‡a
Muggia, Franco M.
-
100 1 _
‡a
Muggia, Franco M.
‡d
1936-
-
100 1 _
‡a
Muggia, Franco M.
‡d
1936-
-
100 1 _ ‡a Muggia, Franco M., ‡d 1936-
4xx's: Alternate Name Forms (13)
Works
| Title | Sources |
|---|---|
| Adriamycin : its expanding role in cancer treatment : proceedings of the International Symposium on Adriamycin, July 14-16, 1983 Hakone, Japan |
|
| Cancer chemo- and immunopharmacology |
|
| Clinical evaluation of anti-tumor therapy |
|
| Concepts, clinical developments, and therapeutic advances in cancer chemotherapy |
|
| Concepts, mechanisms, and new targets for chemotherapy |
|
| Etoposide (VP-16), 1984: |
|
| Liver cancer |
|
| Lung cancer, 1979 (a.e.) |
|
| New drug therapy |
|
| Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy : Molecular Mechanisms and Clinical Applications |
|
| Re: Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes |
|
| Repeated femoral vein cannulation for administration of chemotherapeutic agents |
|
| 'Retarded pharmaceuticals' assuming a clinical role |
|
| Reticulum cell sarcoma of the spinal epidural space |
|
| Role of a nitrosourea (CCNU, NSC-79037) in advanced nonhematologic cancer |
|
| The role of anthracyclines in the treatment of gastric cancer |
|
| Role of carboplatin in endometrial and cervical carcinomas |
|
| Role of complement activation in hypersensitivity reactions to doxil and hynic PEG liposomes: experimental and clinical studies |
|
| Saline MR peritoneography |
|
| Second National Cancer Institute Conference in Lung Cancer Treatment [Airlie House, Virginia, May 22 - 24, 1977] |
|
| Seminoma and sarcoidosis: a cause for false positive mediastinal uptake in PET? |
|
| Sequential methotrexate and 5-fluorouracil with bleomycin and cisplatin in the chemotherapy of advanced squamous cancer of the head and neck |
|
| Sequential single agents as first-line chemotherapy for ovarian cancer: a strategy derived from the results of GOG-132. |
|
| Sequential therapy with INCAGN01949 followed by ipilimumab and nivolumab in two patients with advanced ovarian carcinoma |
|
| Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer |
|
| Simple and sensitive method for the quantitative analysis of lometrexol in plasma using high-performance liquid chromatography with electrochemical detection |
|
| Single-dose dacarbazine and dactinomycin in advanced malignant melanoma |
|
| Squamous cell carcinoma of the oral cavity in nonsmoking women: a new and unusual complication of chemotherapy for recurrent ovarian cancer? |
|
| Squamous cell carcinoma of the rectum: a consequence of immunosuppression resulting from inhibiting tumour necrosis factor (TNF)? |
|
| Squamous cell carcinomas of the tongue and oral cavity as secondary malignancies: what factors are implicated? |
|
| Staging of testicular cancer: a proposed clinical-surgical schema |
|
| Staging relationships and outcome in early stage testicular cancer: a report from the Testicular Cancer Intergroup Study |
|
| Supraventricular tachycardia and urticaria complicating leuprolide-induced ovarian suppression in a young woman with breast cancer: a case report |
|
| Surgical adjuvant trials in the United States |
|
| Surgical treatment for advanced epithelial carcinoma of the ovary |
|
| Targeted agents and oxaliplatin-containing regimens for the treatment of colon cancer |
|
| Targeted therapy: its status and promise in selected solid tumors. Part II: Impact on selected tumor subsets, and areas of evolving integration |
|
| Targeting HER2 in ovarian and uterine cancers: challenges and future directions |
|
| Taxanes in adjuvant and neoadjuvant therapies for breast cancer. |
|
| Teniposide in adult solid tumors: a historical perspective |
|
| Therapeutic approaches in malignant mesothelioma |
|
| Therapeutic progress in ovarian cancer, testicular cancer, and the sarcomas |
|
| Thoughts about September 11, 2001: civilization's resilience and tenacity |
|
| Time relationship between last dose of daunorubicin and congestive heart failure |
|
| Timing is everything: intraperitoneal chemotherapy after primary or interval debulking surgery for advanced ovarian cancer |
|
| Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study |
|
| Tolerance of paclitaxel 3-hour infusion with and without granulocyte colony-stimulating factor on a biweekly schedule |
|
| Tomudex (ZD1694, NSC 639186) in platinum-pretreated recurrent epithelial ovarian cancer: a phase II study by the Gynecologic Oncology Group |
|
| Toxicity comparisons between two chemotherapy regimens as adjuvant or salvage treatment in nonseminomatous testicular cancer |
|
| Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis |
|
| Treatment of advanced Hodgkin's disease with vinblastine (NSC-49842) or procarbazine (NSC-77213) |
|
| Treatment of advanced refractory lymphoma with teniposide and lomustine |
|
| Treatment of colon cancer based on biochemical modulation of fluoropyrimidines by hydroxyurea |
|
| Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin, and vinblastine. |
|
| Treatment of Kaposi's sarcoma: overview and analysis by clinical setting |
|
| Treatment of liver metastases in patients with neuroendocrine tumors of gastroesophageal and pancreatic origin |
|
| Treatment of malignant brain tumors with nitrosoureas |
|
| Treatment of non-small-cell lung cancer with vinblastine and very high-dose cisplatin. A Southwest Oncology Group study |
|
| Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin: analysis of toxicities and predictors of outcome. |
|
| Treatment of primary breast cancer. Summary of the National Institutes of Health Consensus Development Conference |
|
| Treatment of sarcomas: thinking out-of-the-box |
|
| Treatment strategies in relation to drug action |
|
| Tuftsin - unimportant or forgotten |
|
| Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study |
|
| Use of medroxyprogesterone acetate in the treatment of Müllerian adenosarcoma: a case report |
|
| Uterine cancer screening, diagnosis, and treatment |
|
| Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma |
|
| Vascular factors in acute pancreatitis. |
|
| VM-26, a new anticancer drug with effectiveness in malignant lymphoma: an Eastern Cooperative Oncology Group Study (EST 1474). |
|
| VM 26 and VP 16-213: a comparative analysis |
|
| Weekly 5-fluorouracil combined with PALA: toxic and therapeutic effects in colorectal cancer |
|
| Weekly paclitaxel with intermittent imatinib mesylate |
|
| Whatever happened to NSC--? An analysis of clinical results of discontinued anticancer agents. |
|
| Women's cancers: how the discovery of BRCA genes is driving current concepts of cancer biology and therapeutics |
|
| Working conference on mesothelioma treatment trials |
|
